Search - tctmd.com

Displaying 121 - 140 of 162

Sort: Relevancy | Date

Presentation TCT Abstracts Posters 2019

Transcatheter Aortic Valve Replacement in Low-risk Patients A Meta-analysis of Randomized Controlled Trials

Presenter: Ahmad Al-Abdouh

October 06, 2019

Portico Noninferior to Commercial TAVR Valves in IDE Study

News Conference News TCT 2019

Portico Noninferior to Commercial TAVR Valves in IDE Study

September 27, 2019

Point/Counterpoint: Provocative Views #1 - Remaining Data Gaps After the Low-Risk TAVR RCTs

Presentation TCT 2019

Remaining Data Gaps After the Low-Risk TAVR RCTs

Presenter: Michael Borger

September 26, 2019

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

August 21, 2019

Meta-analysis Supports Surgical LAA Occlusion During Cardiac Surgery, but Flaws Found

News Daily News

Meta-analysis Supports Surgical LAA Occlusion During Cardiac Surgery, but Flaws Found

August 16, 2019

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

News Daily News

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

July 29, 2019

TENDYNE: Attributes, Challenges, and Clinical Data (SUMMIT)

Presentation TVT 2019

TENDYNE: Attributes, Challenges, and Clinical Data (SUMMIT)

Presenter: Gorav Ailawadi

June 14, 2019

INTREPID: Attributes, Challenges, and Clinical Data (APOLLO)

Presentation TVT 2019

INTREPID: Attributes, Challenges, and Clinical Data (APOLLO)

Presenter: Martin Leon

June 14, 2019

Reactions From the Surgical Community

Presentation TVT 2019

Reactions From the Surgical Community

Presenter: Patrick McCarthy

June 13, 2019

Reactions From the Cardiology Community

Presentation TVT 2019

Reactions From the Cardiology Community

Presenter: Blase Carabello

June 13, 2019

Highlights From the CoreValve Low-Risk Trial

Presentation TVT 2019

Highlights From the CoreValve Low-Risk Trial

Presenter: Jeffrey Popma

June 13, 2019

Highlights From the PARTNER 3 Low-Risk Trial

Presentation TVT 2019

Highlights From the PARTNER 3 Low-Risk Trial

Presenter: Michael Mack

June 13, 2019

TCTMD’s Top 10 Most Popular Stories for May 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2019

May 31, 2019

MitraClip Benefits FMR Patients Regardless of Baseline BNP: COAPT

News Conference News ESC Heart Failure 2019

MitraClip Benefits FMR Patients Regardless of Baseline BNP: COAPT

May 27, 2019

News Industry News

Cook Medical Provides Patient-Level Paclitaxel Data From Randomised Control Trial

April 19, 2019

First US Consensus Statement on PFO Closure Addresses Volume Requirements, Quality Measurements

News Daily News

First US Consensus Statement on PFO Closure Addresses Volume Requirements, Quality Measurements

Yael L. Maxwell

April 01, 2019

A Randomized Trial Comparing a Novel Sirolimus-Eluting Bioresorbable Scaffold with Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease: Three-Year Results of NeoVas RCT

Presentation CIT 2019

A Randomized Trial Comparing a Novel Sirolimus-Eluting Bioresorbable Scaffold with Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease: Three-Year Results of NeoVas RCT

Presenter: Yaling Han

March 28, 2019

DOACs in Patients With Mitral Stenosis and A-fib: Analysis Suggests a Benefit

News Daily News

DOACs in Patients With Mitral Stenosis and A-fib: Analysis Suggests a Benefit

March 12, 2019

Late Follow-up of PFO Closure for Stroke Raises Questions for Antiplatelet Duration

News Daily News

Late Follow-up of PFO Closure for Stroke Raises Questions for Antiplatelet Duration

January 22, 2019

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

News Daily News

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

January 09, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.